SciClone Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Provides Earnings Guidance for the Year 2017
For the year, the company's total net revenues were $160,096,000 compared to $157,257,000 a year ago. Income from operations was $33,235,000 compared to $29,911,000 a year ago. Income before provision for income tax was $34,133,000 compared to $30,270,000 a year ago. Net income was $30,729,000 compared to $29,463,000 a year ago. Diluted net income per share was $0.58 compared to $0.56 a year ago. Non-GAAP net income was $43,836,000 compared to $52,230,000 a year ago. Non-GAAP diluted net income per share was $0.83 compared to $1.00 a year ago.
The company projects its 2017 revenue to be in the range between $170 and $175 million, driven by ZADAXIN revenues; and its non-GAAP diluted earnings per share to be in the range between $0.60 and $0.64.